Literature DB >> 33861219

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects.

David B Yaden1,2, Roland R Griffiths1,2,3.   

Abstract

Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 33861219      PMCID: PMC8033615          DOI: 10.1021/acsptsci.0c00194

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  30 in total

Review 1.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

2.  Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).

Authors:  Mathias Ebbesen Jensen; Dea Siggaard Stenbæk; Tobias Søgaard Juul; Patrick MacDonald Fisher; Claus Thorn Ekstrøm; Gitte Moos Knudsen; Anders Fink-Jensen
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

Review 3.  Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

Authors:  Albert Garcia-Romeu; Sean Darcy; Hillary Jackson; Toni White; Paul Rosenberg
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 4.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

5.  Psychedelic-inspired drug discovery using an engineered biosensor.

Authors:  Chunyang Dong; Calvin Ly; Lee E Dunlap; Maxemiliano V Vargas; Junqing Sun; In-Wook Hwang; Arya Azinfar; Won Chan Oh; William C Wetsel; David E Olson; Lin Tian
Journal:  Cell       Date:  2021-04-28       Impact factor: 41.582

Review 6.  Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Authors:  David E Olson
Journal:  Biochemistry       Date:  2022-01-21       Impact factor: 3.162

7.  Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.

Authors:  Ling-Xiao Shao; Clara Liao; Ian Gregg; Pasha A Davoudian; Neil K Savalia; Kristina Delagarza; Alex C Kwan
Journal:  Neuron       Date:  2021-07-05       Impact factor: 18.688

8.  The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Authors:  P Mallaroni; N L Mason; F R J Vinckenbosch; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2022-04-30       Impact factor: 4.415

9.  Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.

Authors:  Roberta Murphy; Hannes Kettner; Rick Zeifman; Bruna Giribaldi; Laura Kartner; Jonny Martell; Tim Read; Ashleigh Murphy-Beiner; Michelle Baker-Jones; David Nutt; David Erritzoe; Rosalind Watts; Robin Carhart-Harris
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

10.  Engineering Safer Psychedelics for Treating Addiction.

Authors:  Jamie Peters; David E Olson
Journal:  Neurosci Insights       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.